What Is MAI Lung Disease? Causes, Symptoms & Treatment

MAI lung disease is a chronic infection of the lungs caused by bacteria in the Mycobacterium avium complex, a group of slow-growing organisms found naturally in water and soil. Unlike tuberculosis, which spreads person to person, MAI is picked up from the environment, and the infection tends to develop gradually over months or years. The disease has been rising steadily worldwide, and diagnosing it often takes the better part of a year because symptoms overlap with many other respiratory conditions.

The Bacteria Behind the Disease

Mycobacterium avium complex (MAC) refers primarily to two closely related species, M. avium and M. intracellulare, though a few additional subspecies sometimes get grouped in. These bacteria belong to a larger family called nontuberculous mycobacteria (NTM), which includes over 200 species. MAC accounts for the majority of NTM lung disease cases worldwide.¹ The organisms are hardy: they resist standard water disinfection methods, tolerate high temperatures, and form stubborn biofilms that cling to surfaces inside plumbing systems.²

When you inhale MAC bacteria, your immune system’s first responders, macrophages, attempt to engulf and destroy them. MAC organisms, however, have evolved mechanisms to survive inside macrophages, interfering with the normal process by which immune cells digest foreign invaders.³ This ability to persist inside the very cells meant to kill them is a major reason why MAC infections are so difficult to clear and why treatment takes so long.

Where People Catch It

You do not catch MAI lung disease from another person. The bacteria live in the environment, and the main route of infection is inhaling contaminated water droplets or soil particles. Household water systems are a well-documented source. MAC has been isolated from showerheads, hot water tanks, bathtub drains, and the aerosol mist generated during showers.² It has also been found in potting soil, which can release the organisms into the air when disturbed.

Among these environmental reservoirs, shower aerosols appear to carry the strongest link to actual disease. A case-control study found that detecting NTM in shower aerosols was associated with roughly four times the odds of having MAC lung disease, while isolating the bacteria from tap water or soil samples did not show the same association.⁴ This makes intuitive sense: a shower produces a fine mist that is easily inhaled deep into the lungs, while simply running a tap creates much less airborne exposure.

Who Is Most Vulnerable

Although anyone can develop MAI lung disease, it disproportionately affects certain groups. People with pre-existing structural lung problems, particularly COPD, bronchiectasis, and cystic fibrosis, are at increased risk because damaged airways are less efficient at clearing inhaled bacteria.⁵ People on immunosuppressive medications, including long-term corticosteroids and biologic drugs for autoimmune conditions, also face elevated risk.

But there is a striking demographic pattern that has puzzled researchers for decades. In patients without obvious prior lung disease, the typical MAC lung disease patient is a thin, older woman. One study of patients without pre-existing lung problems found that about 94% were female, 90% were white, and the median age at diagnosis was 63.⁶ This pattern has been called “Lady Windermere syndrome,” a somewhat outdated and debated term that refers to a particular presentation in tall, slender postmenopausal women.

Several theories try to explain why this body type is at risk. Researchers have noted that many of these patients have skeletal abnormalities like scoliosis or a sunken breastbone, which could reduce the effectiveness of coughing and mucus clearance. Low body fat has been linked to a shift in immune signaling that may weaken a specific arm of the immune system responsible for fighting mycobacteria. Some researchers have also suggested a role for low estrogen, given the predominance of postmenopausal women, though this remains speculative.⁷ The overlap of skeletal abnormalities and mitral valve prolapse in these patients has even led some researchers to wonder whether an underlying connective tissue disorder contributes to susceptibility.

Symptoms and How the Disease Develops

MAI lung disease is a slow-burn infection. The most common symptoms are a persistent cough, often producing mucus, along with fatigue, shortness of breath, and sometimes unintentional weight loss. Some people develop night sweats or low-grade fevers. These symptoms come on gradually and overlap heavily with other respiratory conditions, which is one reason diagnosis is so frequently delayed. In one study, the median gap between symptom onset and diagnosis was ten months.⁶

The disease commonly takes one of two forms on imaging. The more frequent pattern, called the nodular bronchiectatic form, shows small lung nodules and widened airways (bronchiectasis) scattered across multiple lobes. This is the pattern typically seen in the “Lady Windermere” demographic. The second pattern, the fibrocavitary form, involves cavities in the upper lobes and looks more like tuberculosis. This form tends to be more aggressive and progresses faster. In the nodular bronchiectatic form, bronchiectasis or small nodules were found in about 93% of patients.⁶

Getting a Diagnosis

Diagnosing MAI lung disease requires meeting all three of the following criteria: compatible symptoms, characteristic changes on a chest CT scan, and microbiological confirmation from sputum cultures. All three must be present because MAC bacteria are so common in the environment that finding them in a single sputum sample does not prove they are causing disease. Current guidelines recommend at least two positive sputum cultures growing the same MAC species before a diagnosis is made, specifically to guard against false positives from environmental contamination.⁸

A CT scan of the chest is more sensitive than a regular X-ray for this disease. Radiologists look for a combination of bronchiectasis, small inflammatory nodules, areas of consolidation, and in more severe cases, cavities.⁹ When sputum cultures are inconclusive, a bronchoscopy or even a lung biopsy may be needed. In one cohort of patients without prior lung disease, about 45% required bronchoscopy or open lung biopsy because their sputum cultures were not diagnostic on their own.⁶

Not everyone who meets these criteria necessarily needs immediate treatment. For mild nodular bronchiectatic disease, doctors sometimes opt for watchful waiting with periodic imaging and cultures, because some patients remain stable for years without antibiotics. The decision to treat depends on the severity of symptoms, the rate of progression on imaging, and the patient’s overall health and ability to tolerate a long antibiotic regimen.

Standard Antibiotic Treatment

When treatment is warranted, the cornerstone is a three-drug antibiotic regimen. Guidelines recommend combining a macrolide antibiotic (azithromycin or clarithromycin) with rifampin and ethambutol. This combination has been the standard of care since the late 1990s and remains the recommended first-line approach.¹⁰ Treatment must continue for at least twelve months after sputum cultures turn negative, which typically means a total treatment course of eighteen months to two years or more.¹¹

For the nodular bronchiectatic form without cavities, doctors can sometimes prescribe the antibiotics three times per week instead of daily. A study comparing daily and intermittent regimens for recurrent noncavitary nodular bronchiectatic disease found that sputum culture conversion rates were similar at around 81-82% for both approaches.¹² Intermittent dosing can substantially reduce side effects, which matters a great deal given the length of treatment. For cavitary disease or severe presentations, daily dosing is standard, and an injectable aminoglycoside like amikacin or streptomycin may be added for the first few months.

Why Side Effects Are a Serious Problem

The duration and complexity of MAC treatment mean that drug side effects are not just an inconvenience but a major barrier to successful outcomes. The three core drugs each bring their own risks, and combining them over a year or more amplifies the problem. In one early study, more than half of patients did not tolerate their initial multidrug regimen.⁶ The list of potential toxicities includes liver injury, hearing damage, kidney problems, nerve damage, gastrointestinal distress, blood count changes, and skin reactions, and these frequently lead to dose reductions, drug switches, or interruptions that undermine effectiveness.¹³

Ethambutol-related eye problems deserve special attention because they can be serious if missed. Blurred vision and changes in color perception are the hallmark signs. In large treatment cohorts, confirmed eye toxicity from daily ethambutol occurred in roughly 3-8% of patients, though the number who experienced visual symptoms prompting an eye exam was much higher, around 43% in one cohort. The risk increases with longer exposure and typically appears after more than six months of treatment. Most cases are reversible if the drug is stopped promptly, and expert panels overwhelmingly agree that confirmed eye toxicity means stopping ethambutol.¹⁴ Regular eye exams throughout treatment are considered essential. Dropping ethambutol without adding a replacement drug is common in practice but dangerous because it can allow the bacteria to develop resistance to the macrolide, potentially making the infection much harder to treat.

The macrolide component also carries side effects. Tinnitus (ringing in the ears) occurred in roughly 18-46% of patients taking high-dose azithromycin in two treatment cohorts. When aminoglycosides are added for severe disease, hearing loss becomes an additional concern, observed in over a quarter to nearly half of patients depending on the specific drug used.¹⁴

When First-Line Treatment Fails

Treatment failure is not rare. Roughly half of patients in some studies fail their initial regimen, and even among those who successfully clear the bacteria, the infection comes back in a substantial minority. Clinical recurrence has been estimated at 10 to 40% of treated patients.¹⁵ Determining whether a recurrence is a true relapse from the original strain or a new infection from the environment is clinically important because it changes the treatment approach and helps avoid unnecessary escalation of antibiotics.¹⁶

For patients whose disease does not respond to the standard oral regimen, one of the most significant advances in recent years has been amikacin liposome inhalation suspension (ALIS), an inhaled formulation that delivers the antibiotic directly to the lungs. In a randomized trial, adding ALIS to a standard background regimen achieved sputum culture conversion in about 29% of patients by six months, compared with roughly 9% in the group receiving the background regimen alone. The benefit was durable: about 16% of the ALIS group maintained conversion through twelve months and remained culture-negative three months after stopping all MAC treatment, compared with none in the control group.¹⁷ Longer exposure improved results further, with conversion rates climbing to about a third of patients by twelve months in an open-label extension.¹⁸ These numbers may seem modest compared to what we expect from antibiotics in other infections, but in the context of refractory MAC disease, they represent meaningful progress.

Surgery as an Option

For a carefully selected group of patients, removing the most heavily diseased portion of the lung can dramatically improve outcomes. Surgery is typically considered when antibiotic therapy has failed to clear cultures, when a patient has recurrent bleeding from the lungs, or when disease is concentrated in a resectable area. A systematic review and meta-analysis found that the weighted proportion of patients who cleared their cultures after surgery was about 93%, with a recurrence rate of around 9% over a median follow-up of about three years. Postoperative complications occurred in roughly 17% of patients, and in-hospital mortality was essentially zero.¹⁹

A separate long-term study followed patients for years after surgery and found that cure with culture conversion was achieved in 90% of cases, though recurrence eventually occurred in about a third of those patients. Roughly half of those recurrences turned out to be reinfection with a different NTM species or subspecies rather than true relapse.²⁰ This highlights a frustrating reality: because MAC is everywhere in the environment, even successful treatment does not make you immune to catching it again. Encouragingly, macrolide resistance, a feared complication that can make the bacteria nearly untreatable, did not worsen surgical outcomes in a multicenter study, though older age and not receiving amikacin were independent risk factors for relapse after surgery.²¹

Airway Clearance and Pulmonary Rehabilitation

Antibiotics and surgery get the most attention, but nonpharmacological support plays a real role in managing MAI lung disease. Airway clearance techniques, which include breathing exercises, chest percussion, and devices that use vibration or positive pressure to loosen mucus, help patients move secretions out of damaged airways. A pulmonary rehabilitation program can combine these techniques with exercise training and education to improve breathlessness and quality of life.²²

Despite the intuitive value of airway clearance, adoption is inconsistent. Data from a large U.S. bronchiectasis registry showed that only about 56% of bronchiectasis patients used any form of airway clearance, and adherence tended to drop over time. There is indirect evidence that it works: among patients with mild NTM lung disease who did not receive antibiotics but continued airway clearance, 30 to 50% spontaneously cleared the bacteria from their sputum cultures.²³ That spontaneous clearance rate is a useful reminder that not every positive culture requires a grueling antibiotic course, and that supporting the body’s own defenses through mucus clearance has real value.

Reducing Exposure at Home

Because reinfection from the environment is a genuine concern even after successful treatment, reducing household MAC exposure makes practical sense, particularly for people who have already had the disease or who have known risk factors. Showerheads are a primary target. Cleaning or replacing showerheads periodically can reduce biofilm buildup, and some experts recommend using point-of-use water filters. A small pilot study found that running a household dehumidifier and ventilating the bathroom after showering eliminated detectable NTM from bathroom air, even though the organisms were present in shower biofilms. While the sample size was limited, the intervention is cheap and low-risk.²⁴

Gardening is another potential source of exposure. Disturbing potting soil or mulch can aerosolize MAC organisms, so wearing a mask during these activities and wetting down soil before handling it are reasonable precautions for high-risk individuals. Hot tubs, which generate heavy aerosol loads, are sometimes flagged as a risk, though the classic “hot tub lung” syndrome is more often associated with a different NTM species.

A Disease That Is Becoming More Common

Rates of NTM lung disease, including MAC, have been climbing worldwide. A systematic review found that about 82% of published studies reported increasing trends in NTM lung infection, with an overall annual rate of change of roughly 4% per year for both infection and disease.²⁵ The number of deaths attributable to NTM disease has also been rising.²⁶

Several explanations probably contribute. Populations are aging, and more people are living with chronic lung disease or taking immunosuppressive medications. Diagnostic awareness has improved and CT scans have become more routine, so cases that were previously missed are now being caught. There may also be genuine environmental factors at play. Modern plumbing systems, which use lower water temperatures for energy efficiency and different disinfection methods, may inadvertently create friendlier conditions for NTM growth. Whatever the combination of causes, clinicians who treat respiratory infections are seeing more MAC lung disease than they did a generation ago, and the infrastructure for diagnosing and managing it is still catching up in many regions.

Living With the Disease Long-Term

MAI lung disease is not typically a rapid killer, but it can significantly erode quality of life. The combination of chronic respiratory symptoms, treatment side effects, and the sheer length of therapy takes a toll. A study tracking patient-reported outcomes during the first six months of MAC treatment found measurable improvements in respiratory symptom scores and physical functioning, suggesting that effective treatment does translate into feeling better in daily life.²⁷ But those gains have to be weighed against the burden of daily or thrice-weekly multidrug regimens, regular blood draws, eye exams, hearing tests, and periodic sputum collections for culture.

Patients often describe feeling isolated by a disease few people around them have heard of. Finding a physician with specific NTM expertise can itself be a challenge, particularly outside major academic medical centers. Patient advocacy groups and online communities have become important resources, and referral to a center experienced in NTM management is worth pursuing if treatment is going poorly or side effects are becoming unmanageable. The disease rewards patience, persistence, and a treatment team willing to adjust the regimen as problems arise rather than abandoning it at the first sign of trouble.

1
PubMed Central. Nontuberculous Mycobacteria-Overview
2
PubMed Central. Association between Mycobacterium avium Complex Pulmonary Disease and Mycobacteria in Home Water and Soil A Case–Control Study
3
American Society for Microbiology (Infection and Immunity). Nontuberculous Mycobacteria, Macrophages, and Host Innate Immune Response
4
Annals of the American Thoracic Society. Association between Mycobacterium avium Complex Pulmonary Disease and Mycobacteria in Home Water and Soil: A Case–Control Study
5
PubMed Central. Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients
6
Chest. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations
7
PubMed Central. Lady Windermere Syndrome: Unravelling an Older Lady’s Nightmare
8
Clinical Infectious Diseases. ATS/ERS/ESCMID/IDSA Clinical Practice Guideline on the Treatment of Nontuberculous Mycobacterial Pulmonary Disease
9
PubMed Central. Natural course of the nodular bronchiectatic form of Mycobacterium Avium complex lung disease: Long-term radiologic change without treatment
10
Ewha Medical Journal. Current and emerging treatment strategies for Mycobacterium avium complex pulmonary disease: a narrative review
11
PubMed Central. Treatment of Mycobacterium avium Complex Pulmonary Disease
12
PubMed Central. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease
13
PubMed. Adjunctive and supportive strategies to mitigate drug toxicities in the treatment of nontuberculous mycobacterial disease with future directions
14
PubMed Central. Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey
15
Annals of the American Thoracic Society. Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility
16
PubMed Central. Understanding recurrence in Mycobacterium avium complex pulmonary disease: genotypic strategies to support clinical decision-making
17
Chest. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure
18
PubMed Central. Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
19
PubMed. Outcomes of Adjunctive Surgery in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-analysis
20
Open Forum Infectious Diseases. Long-term Outcomes of Adjunctive Lung Resection for Nontuberculous Mycobacteria Pulmonary Disease
21
PubMed Central. Impact of Surgical Intervention in Patients With Macrolide-Resistant Mycobacterium avium Complex Pulmonary Disease: A Multicentre Study
22
PubMed. Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease
23
PubMed Central. Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
24
PubMed Central. Shower dehumidification to reduce nontuberculous mycobacteria aerosolization
25
International Journal of Infectious Diseases. Global trends of pulmonary non-tuberculous mycobacteria infection and disease: a systematic review
26
PubMed Central. The Rise of Non-Tuberculosis Mycobacterial Lung Disease
27
PubMed Central. Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease